DNA photo
  Children's Hospital Research  Children's Hospital Labs
Andrew Kung, MD, PhD  Children's logo  Harvard logo
 Andrew Kung, MD, PhD
 X  X
   Department  Hematology/Oncology
   Hospital Title  Assistant in Medicine
   Academic Title  Assistant Professor of Pediatrics
   Phone  617-632-5731
   Fax  617-582-8096
   Email  Andrew Kung
   Location  Dana-Farber Cancer Institute
44 Binney Street
Boston MA 02115
Research Overview

Andrew Kung's research interests are centered on understanding basic mechanisms contributing to tumorigenesis, and extending basic research insights to the development of rationally designed anti-cancer therapeutic strategies.  He and his colleagues have a particular interest in aberrant signal transduction and transcriptional pathways associated with tumorigenesis.

Their research program extends from very basic tumor biology to the development of phase I clinical trials.  They utilize a variety of experimental approaches, including diverse molecular and cell biological techniques, viral vectors, gene expression profiling, mouse genetic models, in vivo cellular and molecular imaging, high-throughput screening assays, biochemistry, and proteomic analysis. They have ongoing internal and external collaborations with academic scientists, clinicians, and industry.  Active areas of research include:

  • Role of hypoxia-regulated gene expression in tumorigenesis and angiogenesis.
  •     
  • Discovering therapies targeting hypoxia-inducible transcription.
  •     
  • Validation and development of therapies targeting IGF/IGF-1R.
  •     
  • Elucidating mechanism of p300/CBP hematologic tumor suppression.
  •     
  • Control of hematopoietic stem cell fate decisions by p300/CBP.
  •     
  • Development of therapeutics targeting CXCR4 in brain tumors.
  •     
  • Discovery of novel targets in acute leukemia.
  •     
  • Development of therapies targeting histone modifying activities.
  •     
  • In vivo cellular and molecular imaging for studying tumor biology.
  •     
  • Development of clinically relevant preclinical models for drug evaluation.
About Andrew Kung

Andrew Kung received his MD from Stanford University School of Medicine. He completed an internship and residency at Children's Hospital Boston and a fellowship at Children's Hospital Boston and Dana-Farber Cancer Institute.

Dr. Kung received the Howard Temin Award from the National Cancer Institute in 2001. He has been a Fellow in the Howard Hughes Medical Institute.

Key Publications
  • Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, Hofmann F, Garcia-Echeverria C, Pearson MA, Anderson KC, Kung AL.  Inhibition of the Insulin-Like Gorwth Factor Receptor-1 Tyrosine Kinase Activity as a Therapeutic Strategy for Multiple Myeloma, Other Hematologic Malignancies and Solid Tumors.  Cancer Cell  2004, 5: 221-230.

  • Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, Memmert K, Naegeli HU, Petersen F, Eck MJ, Wood AW, Livingston DM.  Small Molecule Blockade of Transcriptional Co-Activation of the Hypoxia-Inducible Factor Pathway. Cancer Cell  2004, 6: 33-43.

  • Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright R, Wagner G, Verdine GL, Korsmeyer SJ.  Activation of Apoptosis In Vivo by a Hydrocarbon-Stapled BH3 Helix.  Science  2004, 2004, 305: 1466-1470.
 X  X